Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
Formato:	Journal article
Idioma:	English
Publicado em:	Cell Press 2017

Registros relacionados

Myelodysplastic syndromes: moving towards personalized management
por: Eva Hellström-Lindberg, et al.
Publicado em: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
por: Pellagatti, A, et al.
Publicado em: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
por: Boultwood, J, et al.
Publicado em: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
por: Pellagatti, A, et al.
Publicado em: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
por: Pellagatti, A, et al.
Publicado em: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
por: Jädersten, M, et al.
Publicado em: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
por: Follo, M, et al.
Publicado em: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
por: H. Dohner, et al.
Publicado em: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
por: Garcia-Manero, G, et al.
Publicado em: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
por: Boultwood, J, et al.
Publicado em: (2012)

5q- syndrome.
por: Boultwood, J, et al.
Publicado em: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
por: Svensson, T, et al.
Publicado em: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
por: A. Schuh, et al.
Publicado em: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
por: Garcia-Manero, G, et al.
Publicado em: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
por: Garcia-Manero, G, et al.
Publicado em: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
por: L. Adès, et al.
Publicado em: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
por: S. de Botton, et al.
Publicado em: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
por: Nikpour, M, et al.
Publicado em: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado em: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
por: R Edlin, et al.
Publicado em: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
por: R Edlin, et al.
Publicado em: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
por: A. Schnegg-Kaufmann, et al.
Publicado em: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
por: Garcia-Manero, G, et al.
Publicado em: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
por: Pellagatti, A, et al.
Publicado em: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
por: Pellagatti, A, et al.
Publicado em: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado em: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
por: Pellagatti, A, et al.
Publicado em: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
por: Pellagatti, A, et al.
Publicado em: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
por: Scharenberg, C, et al.
Publicado em: (2011)

Gene expression profiling in the myelodysplastic syndromes.
por: Pellagatti, A, et al.
Publicado em: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
por: Sara Mongiorgi, et al.
Publicado em: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
por: Armstrong, R, et al.
Publicado em: (2017)

Advances in the 5q- syndrome.
por: Boultwood, J, et al.
Publicado em: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
por: Pellagatti, A, et al.
Publicado em: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Anjali Bhatt, et al.
Publicado em: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
por: Chiara R. Dart, et al.
Publicado em: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
por: Nikpour, M, et al.
Publicado em: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
por: Nikpour, M, et al.
Publicado em: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
por: Nikpour, M, et al.
Publicado em: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
por: Nikpour, M, et al.
Publicado em: (2010)